Item 2.02. Results of Operations and Financial Condition.

On March 26, 2020, Prevail Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2019. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



                Exhibit
                  No.      Description

                99.1         Press Release dated March 26, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses